Aytu Biopharma, Inc (NASDAQ: AYTU)

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001385818
Market Cap 17.33 Mn
P/B 1.22
P/E -0.71
P/S 0.28
ROIC (Qtr) -20.30
Div Yield % 0.00
Rev 1y % (Qtr) -6.51
Total Debt (Qtr) 20.93 Mn
Debt/Equity (Qtr) 1.47

About

Aytu BioPharma, Inc., often recognized by its stock symbol AYTU, operates in the pharmaceutical industry, specifically focusing on commercializing novel therapeutics and consumer healthcare products. The company is segmented into two primary business areas: the Rx Segment, dedicated to prescription pharmaceutical products, and the Consumer Health Segment, concentrating on various consumer healthcare products. The Rx Segment is committed to commercializing prescription pharmaceutical products, with its primary offerings being Adzenys XR-ODT and...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 30.02M provide 2.75x coverage of short-term debt 10.93M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 78.42M provides 3.75x coverage of total debt 20.93M, indicating robust asset backing and low credit risk.
  • Robust tangible asset base of 78.42M provides 7.34x coverage of working capital 10.68M, indicating strong operational backing.
  • Cash reserves of 30.02M provide solid 0.93x coverage of other non-current liabilities 32.24M, indicating strong liquidity.
  • Cash reserves of 30.02M exceed inventory value of 8.66M by 3.47x, indicating strong liquidity and inventory management.

Bear case

  • Operating cash flow of (595000) barely covers its investment activities of (3.10M), with a coverage ratio of 0.19, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (3.10M) provide weak support for R&D spending of 378000, which is -8.21x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (595000) shows concerning coverage of stock compensation expenses of 649000, with a -0.92 ratio indicating potential earnings quality issues.
  • High receivables of 30.92M relative to inventory of 8.66M (3.57 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • Free cash flow of (698000) provides weak coverage of capital expenditures of 103000, with a -6.78 ratio suggesting additional external financing needs for growth initiatives.

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ZTS Zoetis Inc. 60.50 Bn 29.70 7.78 7.27 Bn
2 TAK Takeda Pharmaceutical Co Ltd 56.17 Bn 77.42 1.96 36.56 Bn
3 HLN Haleon plc 50.10 Bn 27.80 3.57 -
4 TEVA Teva Pharmaceutical Industries Ltd 39.77 Bn 28.20 2.30 17.09 Bn
5 UTHR UNITED THERAPEUTICS Corp 21.67 Bn 17.04 6.93 0.00 Bn
6 VTRS Viatris Inc 17.75 Bn 22.09 1.06 14.44 Bn
7 NBIX Neurocrine Biosciences Inc 14.02 Bn 32.76 5.23 0.43 Bn
8 RGC Regencell Bioscience Holdings Ltd 13.94 Bn -3,890.00 0.00 -

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.10 32.39
EV to Cash from Ops. EV/CFO -19.97 -110.47
EV to Debt EV to Debt 0.57 345.43
EV to EBIT EV/EBIT -0.55 -42.53
EV to EBITDA EV/EBITDA -2.71 -44.40
EV to Free Cash Flow [EV/FCF] EV/FCF -17.02 -54.30
EV to Market Cap EV to Market Cap 0.69 -3.42
EV to Revenue EV/Rev 0.19 -1,175.08
Price to Book Value [P/B] P/B 1.22 36.75
Price to Earnings [P/E] P/E -0.71 -135.15
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 0.36
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.49
Dividend per Basic Share Div per Share (Qtr) 0.00 0.07
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 3.93
Interest Coverage Int. cover (Qtr) -7.92 -38.53
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -152.28 -148.82
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 47.20 45,342.22
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 2.85
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -1,985.81 27.06
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -462.60 19.86
EBIT Growth (1y) % EBIT 1y % (Qtr) -2,696.61 86.71
EBT Growth (1y) % EBT 1y % (Qtr) -542.04 84.03
EPS Growth (1y) % EPS 1y % (Qtr) -247.42 -17.49
FCF Growth (1y) % FCF 1y % (Qtr) -180.23 -53.73
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -5.24 26.02
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.51 0.50
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.46 2.11
Current Ratio Curr Ratio (Qtr) 1.16 3.95
Debt to Equity Ratio Debt/Equity (Qtr) 1.47 -1.12
Interest Cover Ratio Int Coverage (Qtr) -7.92 -38.53
Times Interest Earned Times Interest Earned (Qtr) -7.92 -38.53
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -27.30 -63,232.43
EBIT Margin % EBIT Margin % (Qtr) -34.20 -64,062.36
EBT Margin % EBT Margin % (Qtr) -38.52 -67,582.30
Gross Margin % Gross Margin % (Qtr) 66.80 8,439.27
Net Profit Margin % Net Margin % (Qtr) -39.00 -67,583.72